
SEER
USDSeer Inc. Class A Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$2.140
고가
$2.140
저가
$2.045
거래량
0.04M
기업 기본 정보
시가총액
116.6M
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.12M
거래소
NMS
통화
USD
52주 범위
AI 분석 리포트
마지막 업데이트: 2025년 10월 30일Seer (SEER): Growth Story or Debt Trap? The Data Tells a Conflicted Tale
Generation Timestamp: October 30, 2025, 11:05 AM EDT
The Steady Drumbeat of Corporate News
The news flow for Seer has been professional and consistent. Recent announcements highlight the company's participation in upcoming investor and scientific conferences. This is standard practice for a company in the biotech space, aimed at maintaining visibility with both the financial community and scientific peers. While these press releases don't contain groundbreaking revelations, they paint a picture of a company actively engaging with its industry. The market appears to have taken this news in stride, with no dramatic price reaction directly tied to these specific announcements. It's business as usual on the communications front.
The Chart's Tug-of-War
Looking back over the past three months, SEER's stock chart tells a story of a slow, grinding recovery from its summer lows. The price found a floor near the $2.00 mark in both August and September. A particularly explosive day on August 8th saw the stock leap to $2.30 on a massive surge in trading volume, hinting at strong buying interest at lower levels. Since mid-September, the stock has built a choppy but clear uptrend, recently testing highs around $2.40. However, the climb hasn't been a straight line. The price is currently pulling back from its late-October peak, settling around $2.22. This price action suggests a battle is underway. Buyers have been defending the $2.00-$2.05 area, while sellers are providing resistance above $2.35.
Decoding the Signals
The internal metrics for Seer present a deeply mixed picture. On one hand, the company shows promising signs. Revenue growth is a healthy 31.9%, and its Price-to-Earnings ratio, while negative, is less so than the industry average. This could suggest it is valued attractively relative to its peers. On the other hand, some serious red flags are waving. The company's debt-to-equity ratio is alarmingly high at 8.61, and its Return on Equity is a concerning -25.3%. These figures point to financial strain.
Technical indicators are also sending conflicting messages. While the price has been trending up, indicators like the MACD and DMI are flashing bearish signals, which often precede a downward turn. The AI forecast adds another layer, predicting a flat-to-slightly-down day followed by two days of modest gains. This suggests the immediate future could be choppy, with a slight upward tilt.
| Key Metric | Value | Interpretation |
|---|---|---|
| P/E Ratio | -1.44 | Better than industry average; potential value. |
| Debt-to-Equity | 8.61 | Very high; indicates significant financial risk. |
| Revenue Growth | 31.9% | Strong; a positive sign for the business. |
| MACD / DMI | Bearish | Technical indicators suggest momentum may be fading. |
| AI 3-Day Forecast | +2.76% (net) | Short-term models see a slight bounce. |
The Bottom Line
For an investor with a higher tolerance for risk and a medium-term outlook, Seer presents a complicated case. The combination of strong revenue growth and a potentially attractive valuation is pitted directly against high debt and weak profitability metrics.
The technical picture suggests caution is warranted. While the stock is near a support level, several indicators are pointing to weakness. A potential strategy for an aggressive investor might involve watching for entry points between $2.29 and $2.34, but only if the stock shows renewed strength. A firm stop-loss at $2.05 is critical to manage the risk, given the company's financial leverage. The take-profit target is set at $2.457, just above the recent highs.
This is not a stock for the faint of heart. The high debt is a major concern that cannot be overlooked. Any position should be considered speculative and sized accordingly.
Disclaimer: This report is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation of an offer to buy any security. The author is not a registered financial advisor. All investment decisions should be made with the help of a qualified professional, and you should conduct your own research before making any investment. Investing in stocks involves risk, including the possible loss of principal. The data and analysis presented are based on the information provided and are subject to change without notice.
관련 뉴스
Seer to Participate in Upcoming November Investor Conferences
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
REDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American
AI 예측Beta
AI 추천
업데이트 시간: 2025년 11월 10일 오전 11:34
59.6% 신뢰도
리스크 & 트레이딩
진입점
$2.07
익절
$2.21
손절
$1.85
핵심 요소
관련 주식
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기